INTRODUCTION
Etodolac (R,S) 2-[1,8-diethyl-1,3,4-tetrahydropyrano (3,4-b)indole-1-yl]acetic acid is a nonsteroidal antiinflammatory agent with analgesic and antipyretic properties. Etodolac has inhibitory effect on cyclooxygenase-2 (COX-2) activation (1) . It is used in the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other rheumatic disorders. Its pharmacological activities are related to inhibition of prostaglandin biosynthesis at the site of inflammation and pain. Etodolac has pyrano [3,4-b] indole basic skeleton. In recent studies, compounds, containing the pyrano [3,4-b] indole scaffold have been reported to exhibit anti-hepatitis C virus NS5B polymerase activity (2, 3) . The hepatitis C virus (HCV) is a significant global human pathogen. The HCV NS5B RNAdependent RNA polymerase (RdRp) is crucial for replicating the viral RNA genome and a promising target for new approaches towards treatment of hepatitis C, because the liver cell does not contain any protein with a similar activity.
Gopalsamy et al. previously reported 1,3,4,9-tetrahydropyrano [3,4-b] indole derivatives as potent and selective HCV NS5B inhibitors (4) . Since etodolac contain 1,3,4-tetrahydropyrano [3,4-b] indole tricyclic heterocyclic scaffold similar to that present in Gopalsamy's compounds (4), we decided to explore thiosemicarbazide derivatives of etodolac as potential anti-NS5B agents. The thiosemicarbazide modification at the carboxyl center of etodolac was chosen based on its ability to generate a valuable building block for the synthesis of five-membered heterocycles. Therefore, the thiosemicarbazide is a highly efficient pharmacophore in molecular design. On the other hand, various derivatives of thiosemicarbazide have been reported to possess interesting biological activities such as antimicrobial (5) (6) (7) (8) , anticonvulsant (9) , antibacterial (10) (11) (12) , antifungal (13) (14) (15) (16) (17) , anti-inflammatory (18, 19) antiviral (20) and anticancer activities (21) (22) (23) (24) . In this study, we have explored the therapeutic potential of the thiosemicarbazide scaffold against HCV NS5B. The inhibitory potency of thiosemicarbazide against HCV replicase has not been examined to-date. [3,4-b] indole-1-yl) acetylhydrazono)-2-alkyl/aryl-4-thiazolidinones [25] , we present in this work novel etodolac thiosemicarbazide derivatives (3a-h) and investigation of their HCV NS5B polymerase inhibitory activity. The characterization of these compounds were identified with the help of elemental analysis, UV, FT-IR, 1 H-NMR, 13 C-NMR and LC-MS spectral data while their purities were analyzed by thin layer chromatography (TLC).
EXPERIMENTAL

Chemistry
All chemicals were purchased from Merck, Sigma-Aldrich or Fluka. Reactions were monitored by TLC on silicagel plates purchased from Merck. Melting points of the synthesized compounds were determined in Schmelzpunktgerät SMP II melting point apparatus and uncorrected. Purity of the compounds was checked TLC plates precoated with silica gel G using solvent systems M1, petroleum ether: ethyl acetate Etodolac (0.01 mol) and methanol (16 mL) were refluxed for 3 h in a few drops of concentrated sulfuric acid. The contents of the flask were subsequently cooled and neutralized by using NaHCO 3 (5%). The resulting precipitate was filtered, dried and recrystallized twice from ethanol to obtain compound 1.
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Biological activity
HCV NS5B polymerase inhibitory activity
All synthesized compounds were evaluated for inhibition of hepatitis C virus NS5B RNA dependent RNA polymerase activity in primer dependent elongation assays as previously described. The biological activity of the compounds against NS5B polymerase were evaluated in a reaction buffer containing 20 mM Tris-HCl (pH 7.0), 100 mM NaCl, 100 mM sodium glutamate, 0.1 mM DTT, 0.01% BSA, 0.01% Tween-20, 5% glycerol, 20 U/mL of RNase Out, 0.25 μM of poly rA/U12, 25 μM UTP, 2 μCi [∞-32 P]UTP, 300 ng of NS5BCΔ21 and 1.0 mM MnCl 2 with or without inhibitors (100 μM) in a total volume of 25 μl for 1h at 30 o C as previously described (26) (27) (28) . Reactions were terminated by the addition of ice-cold 5% (v/v) trichloroacetic acid (TCA) containing 0.5 mM pyrophosphate. Reaction products were precipitated on GF-B filters and quantified on a liquid scintillation counter. NS5B activity in the presence of DMSO control was set at 100% and that in the presence of the compounds was determined relative to this control.
Molecular modeling
Ligand structure preparation
Etodolac derivatives 3a, 3d and 3e were built using the fragment dictionary of Maestro 9.0 and energy minimized by Macromodel program v9.7 (Schrödinger, Inc., New York, NY, 2009) using the OPLSAA force field with the steepest descent followed by truncated Newton conjugate gradient protocol. The low-energy 3D structures of etodolac derivatives were generated with the following parameters present in LigPrep v2.3: different protonation states at physiological pH, all possible tautomers, ring conformations and stereoisomers. The output obtained from the LigPrep run was used as input for docking simulations.
Protein structure preparation
The X-ray co-crystal structure of HCV NS5B-PF868554 (PDB ID: 3FRZ) obtained from the RCSB Protein Data Bank was used for docking into thumb pocket-II (29) . The protein structure was refined by means of default parameters mentioned in Protein Preparation Tool present in Maestro v9.0 and Impact program v5.5 (Schrödinger, Inc., New York, NY, 2009), in which the protonation states of residues were adjusted to the dominant ionic forms at pH 7.4. Refined HCV NS5B structure was further used to generate energy grid by selecting bound inhibitor (PF868554) as reference ligand.
Docking protocol
The Ligprep file containing etodolac derivatives was docked at the TP-II of NS5B using the "Standard Precision" (SP) Glide docking program v5.0 (Schrödinger, Inc., New York, NY, 2009) and the default parameters. The top scoring pose of 3e within the TP-II was used for graphical analysis. All computations were carried out on a Dell Precision 470n dual processor with the Linux OS (Red Hat Enterprise WS 4.0). Purification of the synthesized compounds in this study was confirmed by thin layer chromatography. The structures of compounds derived from etodolac, were identified with the help of FT-IR, 1 H-NMR, 13 C-NMR and LC-MS spectral data, besides elementel analysis. Etodolac thiosemicarbazides were characterized by IR spectra with C=O band at 1674-1688 cm -1 and C=S band at 1188-1217 cm -1 (20, (30) (31) (32) . The UV data of selected prototype 3a was exhibited characteristic K bands arising from chromophoric C=S group at 244 nm (20) . 1 H-NMR data was also in agreement with the formation of thiosemicarbazides. In the 1 H-NMR spectra, all protons were seen accordingly to the expected chemical shift and integral values. For the thiosemicarbazides, the signals of the proton linked to N 1 -N 2 and N 4 nitrogens were shown at 10.48-10.55, 9.58-9.96 and 7.03-9.08 ppm, respectively. In addition, NH protons of compound 3b was observed to exchange with D 2 O in the spectrum. In the 1 H NMR spectra, all protons were seen accordingto the expected chemical shifts and integration values (7, 11, 33-35.) . In the 13 C-NMR spectra of selected prototype compounds 3a and 3b, thiosemicarbazide C=O gave 170.21 and 168.95 ppm, respectively. The peaks resonated at 183.79 and 170.52 ppm in the 13 C-NMR spectrum of these compounds, assigned for C=S, confirming thione form of thiosemicarbazides (36, 37) . The 13 C-NMR spectra of the compounds displayed the appropriate number of resonances that exactly assembled the number of carbon atoms. The MS-API-ES of the selected compound 3b displayed molecular ion at m/z 388 which confirmed its molecular weight. The major fragmentation pattern involved the cleavage of the CONH-NH-CS bonds of amide moiety (32, 38) . Fragmentation pattern for the representative compound 3b which is given in Scheme 3 also supported the expected structure.
RESULTS AND DISCUSSION
Synthesis of Etodolac thiosemicarbazides
Biological Activity
The ability of the compounds to inhibit HCV NS5B RdRp activity was investigated in vitro by polyrA-U 12 extrension assays described in experimental section (28) . The compounds 3a-h were reconstituted in DMSO as 10 mM stocks, and serially diluted in DMSO to obtain working stocks.
Preliminary screening was carried out at 100 μM to identify a wider range of compounds. Percentage inhibition of HCV NS5B RdRp activity was determined at 0.1 mM concentration of the indicated compounds and represents an average of at least two independent measurements in duplicate. NS5B RdRp activity in the absence of the inhibitor was taken as 100 percent after subtraction of residual background activity. The concentration of DMSO in all reactions was kept constant at 5%.
The compounds exhibited inhibition of NS5B RdRp activity ranging from ~23.4% to 76.2% at 100 μM concentration ( Table 1) . The IC 50 values of compounds exhibiting ≥50% inhibition at 0.1 mM concentration were determined from dose-response curves using 
SCHEME 3. MS fragmentation patterns of compound 3b
8-10 concentrations of each compound in duplicate in two independent experiments. Curves were fitted to data points using nonlinear regression analysis and IC 50 values were interpolated from the resulting curves using GraphPad Prism 3.03 software. Wedelolactone (IC 50 =36.1 μM), a previously characterized NS5B inhibitor, was included as an internal reference standard. To understand the probable molecular mechanism of etodolac derivatives in interfering with NS5B polymerase activity, we have performed molecular docking study using Glide docking software. Since the structurally related pyranoindoles have been previously shown to inhibit NS5B activity through binding to TP-II, we performed docking calculations at TP-II site (3, 39) . Analysis of the binding energy data for the docked conformations of R-versus S-isomers of compounds 3a, 3d and 3e showed that R-isomers bind favorably as compared to their Scounterparts. For example, compounds 3a (Glidescore for R = -5.65 kcal/mol and for S = -5.48 kcal/mol), 3d (Glidescore for R = -6.44 kcal/mol and for S = -5.65 kcal/mol) and 3e (Glidescore for R = -6.71 kcal/mol and for S = -6.62 kcal/mol).
The binding mode of (R)-isomer of the etodolac derivative 3e within the TP-II of HCV NS5B polymerase is shown in Scheme 4. The ethyl substituent on indole nucleus forms hydrophobic interactions with the side chains of Ile482, Val485 and Leu489. The indole nucleus is stabilized by hydrophobic interactions with the side chains of Leu419, Met423, Tyr477, Ile482, and Leu497. The indole ring -NH forms hydrogen bonding interaction with the S atom of Met423 (NH---S-Met423, 2.3 Å). The ethyloxepine moiety is mainly stabilized by hydrophobic contacts with the side chain of Tyr477 and Trp528. The carbonyl oxygen atom of the thiosemicarbazide group forms electrostatic interaction with the backbone -NH of Ser476 (C=O---HN-Ser476, 3.5 Å). One of the -NH group of thiosemicarbazide function may enter into electrostatic interaction with the backbone of Trp528 (-NH---O=C-Trp528, 3.6 Å). The C=S group is stabilized by electrostatic contact with the side chain amide group of Asn527 -C=S---H 2 N-Asn527, 3.5 Å). The terminal allyl group is stabilized by hydrophobic and pi-pi interactions with Ala376 and His475, respectively.
Amino acid residues are shown as stick model with the atoms colored as carbon -green, hydrogen -white, nitrogen -blue and oxygen -red whereas inhibitor is shown as ball and stick model with the same color scheme as above except carbon atoms are represented in orange. Dotted red line indicates hydrogen bonding interaction whereas dotted cyan line indicates potential electrostatic contact with distances in Å.
CONCLUSION
In this study, a series of novel etodolac thiosemicarbazide derivatives were synthesized and evaluated for inhibition of hepatitis C virus NS5B RNA dependent RNA polymerase activity. The etodolac thiosemicarbazides; 3a (IC 50 : 18.7 μM), 3d (IC 50 : 29.2 μM) and 3e (IC 50 : 16.8 μM) are the most potent compounds. Molecular docking and binding mode investigations also suggest that thiosemicarbazide scaffold may be optimized for generating new analogues with improved anti-NS5B potency. Based on these studies, we are now in the process of synthesizing modified analogues in order to generate more effective hepatitis C virus NS5B RNA dependent RNA polymerase inhibitors.
